Bisphosphonates as adjuvant therapy for breast cancer

Current Breast Cancer Reports

Volumn 1, Issue 1, 2009, Pages 54-63

  Gnant, Michael ^a   Dubsky, Peter ^a   Fitzal, Florian ^a   Bachleitner Hofmann, Thomas ^a   Exner, Ruth ^a   Blaha, Peter ^a   Jakesz, Raimund ^a   Schippinger, Walter ^a   Greil, Richard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ALENDRONIC ACID; ANASTROZOLE; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DOXYCYCLINE; EPIRUBICIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; THALIDOMIDE; UFT; ZOLEDRONIC ACID;

ADD ON THERAPY; ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE DISEASE; BONE MARROW BIOPSY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; EVIDENCE BASED PRACTICE; FRACTURE; HORMONAL THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MASTECTOMY; MENOPAUSAL SYNDROME; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOLYSIS; OVERALL SURVIVAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PROGNOSIS; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 77953430938     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-009-0008-2     Document Type: Review

References (57)

1. Garcia M, Jemal A, Ward EM, et al.: Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. American Cancer Society: Breast Cancer Facts & Figures 2007-2008. Atlanta, GA: American Cancer Society; 2007.
3. Doughty JC, Wilson CR, Monypenny IJ, et al.: Distant metastasis: the most common type of early recurrence with adjuvant tamoxifen therapy [SABCS abstract 3057]. Breast Cancer Res Treat 2007, 106 (Suppl 1):S145.
4. •• Gnant MF, Mlineritsch B, Schippinger W, et al.: Adju-vant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12 [ASCO abstract LBA4]. J Clin Oncol 2008, 26 (Suppl):1006s. The ABCSG-12 study in premenopausal women with early breast cancer demonstrated a reduction in DFS and RFS with zoledronic acid plus endocrine therapy compared with endocrine therapy alone.
5. •• Frassoldati A, Brufsky A, Bundred N, et al.: The effect of zoledronic acid on aromatase inhibitor associated bone loss in post menopausal women with early breast cancer receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO-FAST trails [ESMO abstract 185PD]. Annals Oncol 2008, 19 (Suppl 8):viii78. Integrated analyses of the Z-FAST and ZO-FAST trials in postmenopausal women with early breast cancer receiving adjuvant letrozole revealed that upfront treatment with zoledronic acid pro-longed DFS compared with waiting to initiate zoledronic acid until after clinically relevant bone loss in women undergoing aromatase inhibitor therapy.
6. Winter MC, Thorpe HC, Burkinshaw R, et al.: The addi-tion of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumor activity in breast cancer [abstract 5101]. Presented at 31st Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX; December 10-14, 2008.
7. •• Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34:453-475. This in-depth article reviews how bisphosphonates have demon-strated antitumor activity in vitro, in vivo, and in early clinical trials, suggesting additional clinical benefits of this important class of compounds.
8. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
9. Wikman H, Vessella R, Pantel K: Cancer micrometastasis and tumour dormancy. APMIS 2008, 116:754-770.
10. Santini D, Vincenzi B, Avvisati G, et al.: Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002, 8:1080-1084.
11. Santini D, Vincenzi B, Galluzzo S, et al.: Repeated intermit-tent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007, 13:4482-4486.
12. Jagdev SP, Coleman RE, Shipman CM, et al.: The bisphos-phonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001, 84:1126-1134.
13. Witters LM, Crispino J, Fraterrigo T, et al.: Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003, 26:S92-S97.
14. Hiraga T, Ueda A, Tamura D, et al.: Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 2003, 106:973-979.
15. Vogt U, Bielawski KP, Bosse U, Schlotter CM: Breast tumour growth inhibition in vitro through the combina-tion of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004, 12:1109-1114.
16. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, et al.: Sequence-and schedule-dependent enhancement of zole-dronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005, 113:364-371.
17. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I: Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 2005, 16:845-854.
18. Melisi D, Caputo R, Damiano V, et al.: Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 2005, 12:1051-1058.
19. Neville-Webbe HL, Evans CA, Coleman RE, Holen I: Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biol 2006, 27:92-103.
20. Ural AU, Avcu F, Candir M, et al.: In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res 2006, 8:R52.
21. Ottewell PD, Monkkonen H, Jones M, et al.: Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008, 100:1167-1178.
22. Duivenvoorden WC, Vukmirovic-Popovic S, Kalina M, et al.: Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. Br J Cancer 2007, 96:1526-1531.
23. Ottewell PD, Deux B, Monkkonen H, et al.: Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008, 14:4658-4666.
24. Hiraga T, Williams PJ, Ueda A, et al.: Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004, 10:4559-4567.
25. Coleman RE, Major P, Lipton A, et al.: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935.
26. Mystakidou K, Katsouda E, Parpa E, et al.: Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005, 22:195-201.
27. Aviles A, Nambo MJ, Neri N, et al.: Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007, 24:227-230.
28. Zaghloul MS, Boutrus R, El-Hosieny H, et al.: A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients [ASCO abstract 5033]. J Clin Oncol 2008, 26 (Suppl):257s.
29. Aft R, Chavez-MacGregor M, Trinkaus K, et al.: Effect of zoledronic acid on bone loss in women undergoing chemotherapy for breast cancer [SABCS abstract 505]. Breast Cancer Res Treat 2007, 106 (Suppl 1):S38.
30. Lin AY, Park JW, Scott J, et al.: Zoledronic acid as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow [ASCO abstract 559]. Presented at 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL: May 30-June 3, 2008.
31. Rack BK, Jueckstock J, Genss E-M, et al.: Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer [SABCS abstract 511]. Breast Cancer Res Treat 2007, 106 (Suppl 1):S40.
32. Girardi M: Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol 2006, 126:25-31.
33. Kunzmann V, Bauer E, Feurle J, et al.: Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
34. Sato K, Kimura S, Segawa H, et al.: Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005, 116:94-99.
35. • Santini D, Martini F, Fratto ME, et al.: In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009, 58:31-38. A pilot study of zoledronic acid in patients with breast cancer demonstrated long-term activation of effector γδ T cells, which can exert antitumor effects.
36. • Hadji P, Body JJ, Aapro MS, et al.: Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416. Bisphosphonates are a recommended therapy to prevent bone loss in women receiving aromatase-inhibitor therapy.
37. Powles T, Paterson A, McCloskey E, et al.: Reduction in bone relapse and improved survival with oral clodronate for adju-vant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
38. Diel IJ, Solomayer EF, Costa SD, et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treat-ment. N Engl J Med 1998, 339:357-363.
39. Diel IJ, Jaschke A, Solomayer EF, et al.: Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long-term follow-up. Ann Oncol 2008, 19:2007-2011.
40. Saarto T, Blomqvist C, Virkkunen P, Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001, 19:10-17.
41. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C: Ten-year follow-up of a randomized controlled trial of adjuvant clo-dronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
42. Ha TC, Li H: Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007, 96:1796-1801.
43. Kristensen B, Ejlertsen B, Mouridsen HT, et al.: Bisphos-phonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008, 47:740-746.
44. •• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al.: Adjuvant endocrine therapy plus zoledronic acid in pre-menopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849. A substudy of the ABSCG-12 study revealed that zoledronic acid prevented CTIBL in premenopausal women with early breast cancer receiving endocrine therapy compared with endocrine therapy alone.
45. Brufsky A, Bundred N, Coleman R, et al.: Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13:503-514.
46. Schenk N, Lombart A, Frassoladti A, et al.: The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (let) [ECCO abstract 2008]. Eur J Cancer 2007, 5:186.
47. Clinical Trials.gov: Chemotherapy and/or hormone therapy with or without zoledronate in treating women with stage II or stage III breast cancer. Available at http://clinicaltrials. gov/ct2/show/NCT00072020 Accessed December 4, 2008.
48. Clinical Trials.gov: Clodronate with or without chemo-therapy and/or hormonal therapy in treating women with stage I or II breast cancer. Available at http://clinicaltrials. gov/ct2/show/NCT00009945 Accessed December 4, 2008.
49. ADEBAR-Study Group and the Frauenklinik Innenstadt: Simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as extended bisphosphonate and surveillance trial (SUCCESS-Trial). Available at http://www.success-studie.de/a/downloads/study/Studienproto-koll-Success- Version-33pdf. Accessed December 5, 2008.
50. Clinical Trials.gov: Zoledronate, clodronate, or ibandro-nate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00127205. Accessed December 4, 2008.
51. Clinical Trials.gov: Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). Available at http://clinicaltrials.gov/ct2/show/NCT00512993 Accessed December 5, 2008.
52. Clinical Trials.gov: Investigating the biological effects of the addition of zoledronic acid to pre-operative chemotherapy in breast cancer (ANZAC). Available at http://clinicaltrials. gov/ct2/show/NCT00525759?term= breast+zoledronic+acid +chemotherapy. Accessed December 5, 2008.
53. ISRCTN Register: Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients: a randomised, open-label, multicentre study of the European Association of Urology (EAU) in cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). Available at http://www.controlled-trials.com/ISRCTN66626762/zeus. Accessed December 5, 2008.
54. Clinical Trials.gov: RADAR trial - randomized androgen deprivation and radiotherapy. Available at http://clinicaltrials. gov/ct2/show/NCT00193856 Accessed December 5, 2008.
55. Clinical Trials.gov: Androgen suppression alone or combined with zoledronate, docetaxel, prednisolone, and/or celecoxib in treating patients with locally advanced or metastatic prostate cancer Available at http://clinicaltri-als.gov/ct2/show/NCT00268476?term=stamped&rank=1. Accessed December 5, 2008.
56. Clinical Trials.gov: A study to evaluate the safety and effi-cacy of zoledronic acid in the prevention or delaying of bone metastasis in patients with stage IIIA and IIIB non-small cell lung cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00172042?term=NCT00172042&rank=1. Accessed December 5, 2008.
57. Clinical Trials.gov: Combination bisphosphonate and anti-angiogenesis therapy with pamidronate and thalidomide Available at http://clinicaltrials. gov/ct2/show/NCT00083382. Accessed December 5, 2008.